‘Gujarat, MP report the highest burden'
Researchers from seven universities and institutes of repute, including Rourkela-based National Institute of Technology (NIT), Amaravati-based SRM University, and US-based Kent State University and Harvard University, found that NCDs such as diabetes, cardiovascular diseases (CVDs), cancer, and chronic respiratory diseases have emerged as the leading causes of death and disability, surpassing infectious diseases.
The study, which analysed the Global Burden of Disease data 2021, said India recorded the highest age-standardised prevalence rate (ASDPR) of NCDs in the region, with 92,134 per one lakh population, well above the global average. While age-standardised death rates decreased marginally by 1% between 2010 and 2021, the absolute number of deaths and disability-adjusted life years (DALYs) lost to NCDs continued to rise, driven largely by factors like rapid population growth, ageing demographics, and sedentary lifestyle.
Among the states, Gujarat reported the highest ASDPR of 93,527, followed by Madhya Pradesh (93,107), Assam (92,649), Chhattisgarh (92,555), Bihar (92,547), Jharkhand (92,247), Telangana (92,208), Tripura (92,182), Meghalaya (92,169), Uttar Pradesh (92,064) and Uttarakhand (92,013). The ASDPR in the rest of the states is below the national average.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
an hour ago
- Time of India
Glenmark, Alembic Pharma, Sun Pharma recall products in US: USFDA
Drug makers Glenmark , Alembic Pharmaceuticals and Sun Pharma are recalling products in the US due to manufacturing issues, according to the US health regulator. Independence Day 2025 Modi signals new push for tech independence with local chips Before Trump, British used tariffs to kill Indian textile Bank of Azad Hind: When Netaji Subhas Chandra Bose gave India its own currency Mumbai-based Glenmark is recalling two products in the market, the US Food and Drug Administration ( USFDA ) said in its latest Enforcement Report. Glenmark Pharmaceuticals Inc, USA, a subsidiary of the company, is recalling Carvedilol tablets, used to treat heart failure, hypertension, and heart attack, in multiple strengths. The New Jersey-based firm is recalling 55,560 units of the affected lot due to "presence of a nitrosamine, N-Nitroso Carvedilol impurity above the current acceptable intake level," the USFDA stated. The company is also recalling 17,496 bottles of Carvedilol tablets as "results for N-Nitroso Carvedilol Impurity-1 (NNCI) impurity observed to be above the FDA-recommended limit of NMT 4.0 ppm," it added. Live Events Glenmark initiated the Class II recall in August this year. USFDA said the company is also recalling 22,656 bottles of Theophylline extended-release tablets (400 mg) for failed dissolution specifications. Alembic Pharmaceuticals is recalling 9,492 bottles of Doxepin Hydrochloride capsules, used in the treatment of insomnia, the US health regulator stated. The Class II recall is due to the "Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit," it said. The company initiated the recall on July 25 this year. New Jersey-based Sun Pharmaceutical Industries Inc is recalling 11,328 bottles of Spironolactone Tablets, used to treat high blood pressure, due to "Presence of foreign substance: identified as aluminum," the regulator said. The company commenced the Class II recall on August 5. As per the USFDA, a Class-II recall is initiated when the use of, or exposure to, a violative product may lead to temporary or medically reversible health consequences, or when the likelihood of serious adverse health outcomes is minimal.
Time of India
an hour ago
- Time of India
Not bank balance or luxury flats. Bengaluru startup founder says young professionals are missing the only real asset that matters
Health- A compounding asset In a world obsessed with assets, savings, and investments, it's easy for young professionals to lose sight of what really matters. Many in their mid-20s to mid-30s are caught up worrying about houses, cars, and long-term financial plans, rarely pausing to consider whether they will be healthy enough to enjoy them. Shyam Achuthan, a Bengaluru-based startup founder, recently took to LinkedIn to challenge this mindset and highlight the overlooked 'asset' that drives everything else—your pointed out the irony in chasing things that outlast us while ignoring the very body and mind that need to carry us through life. Houses are designed to last 75 years, cars may survive 15, and investments can potentially grow across generations. Yet, none of these assets truly matter if your health doesn't last even half of that. According to him, a house can outlive you, a car can outlast you, and your money can outgrow you—but if your physical and mental well-being falters, you won't have the energy or ability to enjoy any of Achuthan, health is not just a side priority—it's the ultimate compounding asset. He stresses simple, actionable choices: prioritising sleep over endless screen time, moving your body rather than staying glued to meetings, and focusing on proper nutrition rather than obsessing over net worth. These choices, he explains, compound over time, just like investments, but with one major difference: they determine whether you have the vitality to actually live the life you're message resonates especially with young professionals who are constantly hustling, often sacrificing personal well-being for career goals or material gains. Achuthan urges a shift in mindset—don't just live for things that last, live for the life that lasts within you. By valuing health as the primary asset, every other pursuit becomes more meaningful and sustainable. After all, money, property, and luxury items are tools, but your health is the foundation that lets you truly enjoy them.
India Today
an hour ago
- India Today
IIT Madras licenses India's first silicon photonics quantum random generator
IIT Madras has taken a major step in advancing India's quantum innovation ecosystem by developing and licencing the nation's first silicon photonics-based high-speed Quantum Random Number Generator (QRNG).The deal, valued at Rs 1 crore, has been signed with Indrarka Quantum Technologies Pvt Ltd for its commercial landmark technology was created at the Centre for Programmable Photonic Integrated Circuits and Systems (CPPICS), IIT Madras, and marks the beginning of indigenous field-deployable quantum solutions for national and global applications. The licencing agreement was formalised on August 18, 2025, through the institute's Technology Transfer INNOVATION FOR SECURE TECHNOLOGIES Highlighting the importance of the breakthrough, Professor V Kamakoti, Director, IIT Madras, said, 'Silicon photonics is an emerging area with strong interface with Quantum Technologies. Random number generation is a critical building block for secure computing and communication. I am extremely excited that the CPPICS has developed this QRNG that could be readily deployed in the market.'A prototype of the QRNG was earlier delivered to the Defence Research and Development Organisation (DRDO) and a refined version deployed at the Society for Electronic Transactions and Security (SETS Chennai) for quantum security APPLICATIONS ACROSS SECTORSThe quantum random generator has wide-ranging uses, including IT security for military and defence, cryptographic algorithms, quantum key distribution, scientific modelling, blockchain systems, financial transactions, OTP generation, and even generating truly random numbers, it addresses one of the most critical needs in encryption and secure Soni, Executive Director of Indrarka Quantum Technologies, said, 'We are honoured to partner with IIT Madras in bringing India's first Silicon Photonics-based QRNG to market. This ground-breaking technology represents a significant leap forward in quantum security solutions and exemplifies the success of the Make in India initiative.'ACADEMIC RESEARCH TRANSLATED INTO INDUSTRY SOLUTIONThe MoU signing ceremony was attended by senior officials from the Ministry of Electronics and Information Technology (MeitY), SETS Chennai, and industry partners, underscoring the significance of the the product launch, MeitY Secretary S Krishnan, IAS, congratulated the CPPICS team, describing the innovation as 'a pride for India.'Professor Manu Santhanam, Dean (IC&SR), IIT Madras, said the licencing demonstrates how focused research, combined with industry partnerships, can deliver transformative technologies of national Bijoy Krishna Das, Chief Investigator of CPPICS, added, 'I believe the field-deployable QRNG module is the first silicon photonics-based product from India — a remarkable milestone in our nation's research journey.'The achievement has been credited to faculty, scholars, and engineers at CPPICS, with packaging support from Izmo Microsystems. By moving cutting-edge academic research into industry, IIT Madras has reinforced India's leadership in quantum security technologies.- Ends
